SynthesisFrontiers in oncology2026
Targeting KRAS
Synthesis in Frontiers in oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: The Kirsten rat sarcoma viral oncogene homolog Methods: The systematic review was registered in the PROSPERO database and conducted in accordance with the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) 2020 guidelines. PubMed, Scopus, and ClinicalTrials.gov were searched for phase III randomized controlled trials (RCTs) conducted between 2023 and 2026. The analysis included the CodeBreaK 200 and KRYSTAL-12 registration programs (including subanalyses), which evaluated monotherapy with sotorasib or adagrasib compared with docetaxel in patients with advanced NSCLC harboring the KRAS Results: Both inhibitors significantly prolonged the median progression-free survival (PFS) and increased the objective response rate (ORR) compared with chemotherapy. Adagrasib demonstrated promising intracranial efficacy but was associated with greater gastrointestinal toxicity and frequent dose reductions. Sotorasib was characterized by a better safety profile and more favorable quality-of-life outcomes for patients, although the assessment of its impact on overall survival (OS) was confounded by a high crossover rate in the registration trial. However, the rapid development of secondary mutations and bypass resistance mechanisms remains the main clinical limitation of both drugs when used as monotherapy. Conclusion: Sotorasib and adagrasib provide clinical benefit in advanced NSCLC with the KRAS Systematic review registration: https://www.crd.york.ac.uk/prospero/, identifier CRD420261427962.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.